Welcome to our investor page | BioNTech
Oct 21, 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases.
Investoren - BioNTech
Willkommen auf der Investor Relations Seite der BioNTech SE. Biopharmaceutical New Technologies ist ein globales, voll-integriertes Immuntherapie-Unternehmen der nächsten Generation, das bei der Entwicklung von Therapien für Krebs und andere schwere Erkrankungen Pionierarbeit leistet.
BioNTech Expands Clinical Oncology Portfolio with First Patient …
MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United ...
Press Releases - BioNTech
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
ESG - BioNTech
BioNTech SE. An der Goldgrube 12. 55131 Mainz, Germany. T: +49 6131 9084-0. F: +49 6131 9084-2121. service@biontech.de. Company. About Research & Innovation Pipeline Manufacturing Careers Covid-19. Quick Links. Newsroom Investors Healthcare Professionals Connect.
BioNTech Announces Positive Topline Phase 2 Results for mRNA ...
MAINZ, Germany, July 30, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced positive topline data from the ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899) in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1 ...
BioNTech Announces Fourth Quarter and Full Year 2023 Financial …
Mar 20, 2024 · Progressed three infectious disease vaccine candidates into clinical evaluation, leveraging BioNTech's mRNA technology and expertise; Fourth quarter and full year 2023 revenues of €1.5 billion and €3.8 billion, respectively; Full year net profit of €0.9billion and fully diluted earnings per share of €3.83 ($4.14 1)
BioNTech Announces Fourth Quarter and Full Year 2022 Financial …
MAINZ, Germany, March 27, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the ”Company”) today reported financial results for the three months and full year ended December 31, 2022, and provided an update on its corporate progress.
BioNTech to Establish Regional Headquarters for South East Asia …
May 10, 2021 · BioNTech to establish first regional hub in Asia Pacific region in Singapore ; Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
BioNTech Receives FDA Fast Track Designation for its FixVac …
MAINZ, GERMANY, November 19, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma. BNT111 is the lead product candidate from ...
- Some results have been removed